RECENT NEWS

Genomics England has announced the appointment of Julian Thomas into the new role of Chief Technology and Product Officer.

The UK government has unveiled details of a new tool which it says will speed up cancer diagnosis and treatment, as part of its major reform to the NHS.

A new report published by the UK Health Security Agency (UKHSA) shows current state of health inequalities in England caused by infectious diseases, as well as environmental health hazards.

Molecular diagnostics firm Seegene has revealed some details of its forthcoming CURECA automated PCR system following its recent launch at the European Society of Clinical Microbiology and Infectious Diseases in Vienna, Austria.

Roche has announced the launch of its Elecsys PRO-C3 test, a new diagnostic solution designed to assess the severity of liver fibrosis in patients showing signs of metabolic dysfunction–associated steatotic liver disease (MASLD).

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a vaccine (Vimkunya) used to prevent disease caused by the chikungunya virus in people 12 years of age and older.

Plans to create the London Cancer Hub, set to be the world’s leading district for cancer research and treatment submitted to Sutton Council. Once built the new centre will create thousands of jobs and contribute £1.2 billion to the UK economy.

IBMS, BD and PLMR Healthcomms have released a new report which highlights the need for more consistent and collaborative approaches to reduce contamination rates, improve diagnostic accuracy and enhance patient care.

BioSkryb Genomics and Tecan Group have introduced a high-throughput single-cell workflow, combining BioSkryb’s 384-well format of the ResolveOME Whole Genome and Transcriptome Single-Cell Core Kit with the Uno Single Cell Dispenser, provided by Tecan.

IBMS, LabMed and RCPath have collaborated to set out a shared position on how UK laboratories can improve oversight, clarify accountability and take a whole-system approach to managing assay performance.

Research scientists have identified five specific blood proteins that can accurately predict a person’s risk for developing a serious form of liver disease as early as 16 years before they experience symptoms, enabling early intervention and possible prevention and treatment, according to a study to be presented at Digestive Disease Week.

A groundbreaking UK research network has been launched to uncover how gut health influences the brain, immune system and mental wellbeing. The project will run for four years and has received £4.5 million in funding from the Biotechnology and Biological Sciences Research Council (BBSRC).

PredxBio, a pioneer in AI-powered spatial biomarker discovery, is to partner with Hamamatsu to deliver next-generation spatial biology solutions for cancer research and therapeutic development.

Complete Genomics, a leading innovator in genomic sequencing, has announced a collaboration with Velsera, a leading global healthcare technology company, to deliver an end-to-end genetic testing solution that integrates DNBSEQ sequencing technology with Velsera's Clinical Genomics Workspace (CGW) data analysis solution.

Gestalt, a leading innovator in AI-powered digital pathology solutions, has raised $7.5 million Series A financing to further develop its AI-powered pathology platform, PathFlow.

Medtech firm Sophia Genetics is to expand its ongoing collaboration with AstraZeneca to accelerate the deployment of MSK-ACCESS liquid biopsy application.

AnalytiChem, manufacturer of laboratory equipment, reagents and consumables, has introduced Redipo, a new range of ready-to-use culture media.

Paige, together with NHS Wales, has announced the launch of a new pilot project at Betsi Cadwaladr University Health Board (BCUHB). The project will evaluate how Paige’s AI-assisted diagnostic application, Paige PanCancer Detect, can streamline pathology workflows and enhance patient care by triaging routine clinical cases.

The UK Health Security Agency (UKHSA), has just published an overarching public health strategy for controlling and eliminating mpox (previously referred to as monkeypox) across the UK, focusing on the next 12-month period.

In collaboration with the National Institute for Health and Care Research (NIHR), the UK government has awarded £2.4 million to progress the development of a novel AI-driven blood test, known as miONCO-Dx.